What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2382.png

 

Xolair (Omalizumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE)1

 

Xolair is indicated as add-on therapy:

 

For the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment1

 

 

Why Xolair?

 

Frame 427318804.png

Generally well tolerated.2

Frame 427318809.png

Weekly itch severity effect was sustained over 24 weeks.3

Frame 427318804-1.png

Provides significant and clinically relevant improvements in many aspects of HRQOL that are important to patients with CSU.4

Frame 427318804-2.png

Xolair achieved the highest mean proportion of angioedema-free days 91.0-96.1% of patients at week 12.3

The complete Xolair approach

Frame 427318814.png

Efficacy

Efficacy
See more details
Hide details
Frame 427318813.png

Dosing

Dosing
See more details
Hide details

Xolair API

PDF
View

HRQoL: Health related quality of life, 
CSU: Chronic spontaneous urticaria, 
API: Abbreviated prescribing information.

References

  1. Xolair® 150 mg powder and solvent for solution for injection Ministry of health (MOH) approved leaflet. approval date: 26/10/2020. 

  2. Sussman G, Hébert J, Gulliver W, et al. Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(7):2372-8. 

  3. Xolair®. Summary of product characteristics (SMPC). Available at: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf. Last accessed at: 08/07/2025. 

  4. Finlay AY, Kaplan AP, Beck LA, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology. 2017;31(10):1715-21.

Approved by Egyptian Drug Authority: HBF0424OA4702/092025. Invalidation date: 03/09/2026. 
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

BF0424OA4706_082025_qrCode (1) 1.png

HBF0424OA4702/092025
03/09/2026